TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01227265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preladenant-matching placebo oral tablet taken twice daily
Study: NCT04005287
Drug: Placebo Low Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Solution
Study: NCT04005287
Drug: Placebo High Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Solution
Study: NCT02737007
Drug: [14C]-GSK3191607
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-GSK3191607 is a solution to be administered intravenously as a single dose infusion over 15 minutes. It is a radio-labeled product; 100 mcg of \[14C\]-GSK3191607 contains approximately 7.4 kilobecquerel (kBq) of \[14C\] radioactivity.
Study: NCT00003605
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04915846
Drug: ApoTamox 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive tamoxifen (ApoTamox) for approximately 6 months (6 months + 1 week). Participants and study staff will be blinded as to whether the participants are starting with the placebo or the drug. Depending on randomization, drug or placebo will be dispensed at the end of the t=0 study visit (Phase 1). Dosing will commence the day after the t=0 study visit. At the end of Phase 1, participants will enter a 'washout' period, when they will cease treatment. After approximately 3 months of washout, participants will cross-over to the other treatment regimen and receive the other interventional product (IP) for the final 6 months of their study participation (Phase 2).
Study: NCT04915846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT01404169
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to donepezil 5 mg or 10 mg tablets taken orally once daily for 24 weeks.
Study: NCT00047528
Drug: Alcon Investigational Agent
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03776500
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo supplied as powder for oral solution
Study: NCT02960204
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00074165
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose 330mg/m2 x 2 days infused IV; Every 4 weeks for up to 1 year
Study: NCT02044809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03225833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride
Study: NCT01566006
Drug: Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin
Study: NCT01981031
Drug: BioChaperone® Combo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
Study: NCT01981031
Drug: Humalog® Mix25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
Study: NCT02439866
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: gelatinous capsules filled with sugar as placebo
Study: NCT02439866
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day (Prednisolone Fort; Sina Daroo, Iran
Study: NCT00409071
Drug: Cocculine®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
Study: NCT00409071
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
Study: NCT06119126
Drug: SDF1
Normalized name: Stromal cell-derived factor 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical SDF application
Study: NCT00768612
Drug: SCA-136 50mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00768612
Drug: SCA-136 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00768612
Drug: SCA-136 300mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03676413
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily inhalation throughout the study
Study: NCT03485404
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: folic acid tablets, 5mg/tablet, 1 tablet/day
Study: NCT03822520
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 400mg capsule
Study: NCT03812874
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: water for injection~Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 12 weeks (Phase II)
Study: NCT05568017
Drug: peptide receptor radionuclide therapy with Y-90-DOTATOC
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with unresectable or borderline resectable pNETs will recive PRRT with 90Y-DOTATOC
Study: NCT00788463
Drug: Intranasal Beclomethasone aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone aerosol intranasal, 100ug each nostril, twice daily for 6 months.
Study: NCT06044467
Drug: Placebo - Study Part One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT06044467
Drug: Placebo - Study Part Two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT01296646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An inactive pill to control for non-pharmacological responses.
Study: NCT04080336
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3hours before IUD insertion.
Study: NCT04080336
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
Study: NCT03484416
Drug: Calcium Carbonate 1500 Mg with Vitamin D
Normalized name: Calcium Carbonate 1500 mg with Vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium and 1,000 IU/day cholecalciferol (Dicamax 1000) for 2 weeks, whereas control group did not
Study: NCT00332241
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, once daily, 8 weeks
Study: NCT00730249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily according to an individual titration schedule
Study: NCT02487069
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX is used in all the patients for GVHD prophylaxis.
Study: NCT01651481
Drug: HCP1102
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01651481
Drug: Singulair and Xyzal
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02179008
Drug: DE-117 Low/Middle Dose ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low/Middle Dose DE-117
Study: NCT02179008
Drug: DE-117 Middle/High Dose ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle/High Dose DE-117
Study: NCT02243306
Drug: GSK1278863
Approvals — FDA: no, EMA: no, PMDA: no
Description: Round, biconvex, white film coated tablet containing 5 mg GSK1278863.
Study: NCT03298802
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum
Study: NCT00171379
Drug: Enteric-Coated Mycophenolate Sodium
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02868801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: same intervention as the experimental group
Study: NCT02477800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01586286
Drug: Placebo Ointment Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
Study: NCT02108795
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children randomised to remifentanil group receive remifentanil 0.05 ug/kg/min. Children randomised to control group receive normal saline (placebo)
Study: NCT02108795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01182636
Drug: Differin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% Topical Gel
Study: NCT01182636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel Base
Study: NCT03202667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with Placebo oral tablet once daily for 28 days
Study: NCT03946592
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inject the Drug into submental fat via subcutaneous
Study: NCT03946592
Drug: DWJ211
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inject the Drug into submental fat via subcutaneous
Study: NCT01808911
Drug: Steroid + cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006786
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006786
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02622568
Drug: Veregen only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Veregen 15% ointment on affected areas twice daily
Study: NCT02558725
Drug: two capsules of aktiferrin F
Approvals — FDA: no, EMA: no, PMDA: no
Description: two capsules of Aktiferrin F or Foliferrin
Study: NCT00002893
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002893
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00872872
Drug: AZT/3TC 2 weeks after delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT/3TC 300/150mg will be given every 12 hours for 1 week after NVP discontinuation in arm 1 and for 2 weeks after NVP discontinuation in arm 2.
Study: NCT00579527
Drug: Methylprednisolone or Prednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroids IV or enterally may be given before and after CTTI or CTTI and parathyroid transplantation. Administration and dosage depends on T cell numbers and symptoms. Pre-transplant steroids may be used when pre-transplant T cells \>4,000cumm. Steroids are weaned as per protocol.
Study: NCT04445935
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive standard anticoagulation with LMWH/UFH
Study: NCT03631433
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: identical appearing tablets containing 600 mg of ibuprofen
Study: NCT03631433
Drug: ibuprofen 600 mg and acetaminophen 650 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: identical appearing tablets of the combination of ibuprofen and acetaminophen
Study: NCT00774397
Drug: BI 201335 NA 240 mg QD / LI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg BI 201335 NA (Faldaprevir) once daily with a 3 days lead-in phase of PegIFN/RB, 24 weeks
Study: NCT00774397
Drug: PegIFN/RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
Study: NCT00774397
Drug: BI 201335 NA 120mg QD / LI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120mg BI 201335 NA (Faldaprevir) once daily, for 24 weeks
Study: NCT00774397
Drug: PegIFN/RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
Study: NCT00774397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03614273
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
Study: NCT05397262
Drug: Chemotherapy 5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/m\^2 civ 120h; d 1-5, 29-33
Study: NCT01195636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily application of Placebo ointment
Study: NCT03961529
Drug: 0.3% OPA-15406 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily
Study: NCT03961529
Drug: 1% OPA-15406 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily
Study: NCT00381706
Drug: ECF
Normalized name: ECF-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: epirubicin and 5-fluorouracil given IV
Study: NCT00381706
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin , leucovorin and 5-fluorouracil IV
Study: NCT01488734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for the fortified mushroom arms
Study: NCT01960764
Drug: Pre-Treatment with Dial liquid antibacterial soap
Normalized name: Dial Antibacterial Soap Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: This arm will be pre-treated with Dial liquid antibacterial soap and alcohol prior to the autologous microbiome transplant.
Study: NCT03069859
Drug: TXA (1g)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram of TXA (10 mL) diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
Study: NCT02445352
Drug: Rosuvastatin 5mg
Normalized name: ROSUVASTATIN 5MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02445352
Drug: DP-R207 5/10mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02445352
Drug: Rosuvastatin 10mg
Normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02445352
Drug: DP-R207 10/10mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00792636
Drug: sumatriptan and naproxen sodium combination tablet
Normalized name: sumatriptan and naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sumatriptan 85mg and naproxen sodium 500mg
Study: NCT00792636
Drug: naproxen sodium tablet
Normalized name: Naproxen Sodium Tablets
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 500mg
Study: NCT02445352
Drug: Rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02445352
Drug: DP-R207 20/10mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02445352
Drug: Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)
Normalized name: ezetimibe 10 MG / rosuvastatin 5 MG [Roszet]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02445352
Drug: Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)
Normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02445352
Drug: Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)
Normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02147431
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 periods of 12 weeks of once weekly dosing, subcutaneous (s.c., under the skin) injection.~Each treatment period will be followed by a hypoglycaemic clamp.
Study: NCT00816894
Drug: D-serine
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes
Study: NCT01746641
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04005781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
Study: NCT03639064
Drug: Cannabis Oil
Normalized name: Cannabis oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed oil cannabis preparation consisting of 3 differing formulations of ∆-9THC and CBD is clinically available in Canada as CanniMed®. The 3 differing formulations of CanniMed® oils contain varying proportions of ∆-9THC and CBD in the following ratios: 18:0; 10:10; 1:20.~All CanniMed® oil formulations consist of cannabinoids extracted from dried cannabis, and diluted in olive oil.
Study: NCT01250236
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium hyaluronate 1.8mg/ml eye drops twice daily
Study: NCT01860794
Drug: Mesencephalic Neuronal Precursor Cells
Normalized name: Bos taurus mesencephalon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.
Study: NCT03610867
Drug: Placebo (SAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive the sample once by oral administration.
Study: NCT00204672
Drug: Achipex
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01468844
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg pink opaque capsule
Study: NCT01468844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02975206
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet
Study: NCT01100203
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg once daily 1 week, then 50 mg once daily for another 23 weeks.
Study: NCT01694459
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions
Study: NCT01694459
Drug: Standard dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.
Study: NCT02227290
Drug: Placebo Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00992485
Drug: ADIPOPLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: autologous adipose-derived stem cell
Study: NCT03016832
Drug: HuangKui Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuangKui Capsule 2.5g/tid, oral dosing.
Study: NCT00144456
Drug: ED-71 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 μg/day(p.o.)for 144 weeks
Study: NCT00002336
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03035058
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03122639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
Study: NCT00141544
Drug: esterified estrogens 1.25 mg and methyltestosterone 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESTRATEST® administered orally QD
Study: NCT00078455
Drug: ILX651
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01209117
Drug: GSK2248761 WBM Capsule
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg GSK2248761 WBM capsule (reference) 2 X100mg
Study: NCT01209117
Drug: GSK2248761 WBM Tablet Formulation 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2248761 WBM Tablet 200mg manufacturing process 1
Study: NCT01209117
Drug: GSK2248761 WBM Tablet Formulation 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2248761 WBM Tablet 200mg manufacturing process 3
Study: NCT01209117
Drug: GSK2248761 WBM Tablet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GSK2248761 WBM tablet 200mg manufacturing process 1, 2, or 3 chosen from Period 1 - 4
Study: NCT00277355
Drug: minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline: Oral; minocycline 100 mg capsules administered twice a day with the morning and evening meal (\~ 8 hours apart)
Study: NCT01514149
Drug: CJC-1134-PC Injection
Normalized name: CJC-1295
Approvals — FDA: no, EMA: no, PMDA: no
Description: CJC-1134-PC administered weekly by subcutaneous injection
Study: NCT01514149
Drug: Weekly placebo for CJC-1134-PC Injection
Normalized name: CJC-1295
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection